

Flutufolastat F 18: Adis Evaluation

Key Points

- An ^{18}F -labelled rhPSMA-targeted imaging agent is being developed by Blue Earth Diagnostics, a subsidiary of Bracco Imaging, for prostate cancer imaging
- Received its first approval on 30 May 2023 in the USA
- Approved for use in adults
Approved for use as a radioactive diagnostic agent for PET of PSMA positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum PSA level

Summary

Flutufolastat F 18 (POSLUMA[®]) is an ^{18}F -labelled radiohybrid (rh) prostate-specific membrane antigen (PSMA)-targeted imaging agent being developed by Blue Earth Diagnostics, a subsidiary of Bracco Imaging, for prostate cancer imaging

In May 2023, flutufolastat F 18 received its first approval in the USA as a radioactive diagnostic agent for positron emission tomography (PET) of PSMA positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level

This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2023.